Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DuacOnce Daily · 1 trial · 1 indication
The assessor performed a count of inflammatory lesions (IL) (papules, pustules, nodules, and cysts), non-inflammatory lesions (NIL) (open and closed comedones) and total lesions (the sum of IL and NIL) at each study visit. Lesion counts were confined to the face. Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at Baseline. Parameters were estimated using analysis of covariance (ANCOVA) with treatment, center, treatment-by-centre interaction and Baseline lesion count in the model. Missing values were imputed using the last observation carried forward (LOCF), i.e., the last available observation was used to estimate subsequent missing data.
ISGA success is defined as the improvement of 2 grades or more in the participant's acne severity scale at Week 12. Acne severity of the participants' face was assessed by the assessor using the ISGA scale, ranging from 0 to 4: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than one small IL; 2=mild, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions \[NLs\]); 3=moderate, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: up to many NILs and ILs, but no more than a few NLs. Missing values were imputed using the LOCF, i.e., the last available observation was used to estimate subsequent missing data.
| Arm | Type | Description |
|---|---|---|
| Duac™Once Daily Gel | EXPERIMENTAL | Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit |
| 1% clindamycin phosphate gel | ACTIVE_COMPARATOR | Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit |
| Name | Type | Description |
|---|---|---|
| Duac™Once Daily Gel | DRUG | 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide |
| 1% clindamycin phosphate gel | DRUG | 1% clindamycin as clindamycin phosphate |
Inclusion Criteria: 1. Male and female subjects between 12 and 45 years of age, inclusive age will be calculated by date of birth, from 0 at birth. 2. Subjects who have: i. A minimum of 17 but not more than 60 facial inflammatory lesions (papules plus pustules), and no more than 1 facial nodula...
DuacOnce Daily is used for the treatment of mild to moderate acne vulgaris. It is a small molecule dermatology drug being developed by GSK plc (GSK). The drug is currently in Phase 3 clinical development and is considered investigational, meaning it is not yet approved for use.
DuacOnce Daily is being developed by GSK plc, which trades under the ticker GSK. The drug is a small molecule therapy intended for the treatment of acne vulgaris and is currently in Phase 3 clinical development.
DuacOnce Daily is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of mild to moderate acne vulgaris.
DuacOnce Daily has one completed Phase 3 clinical trial, identified as NCT01915732. This trial evaluated the efficacy and safety of DuacOnce Daily compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. The trial enrolled 1018 participants in China.
DuacOnce Daily is a formulation of Duac, as indicated by the clinical trial title. The trial compared DuacOnce Daily with clindamycin phosphate gel, and the drug is being developed for the treatment of mild to moderate acne vulgaris.